title: Selected toxicities of targeted therapies: presentation and management.
abstract: The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges. One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies.
authors: Division of Medical Oncology, British Columbia Cancer Agency Vancouver Cancer Centre, Vancouver BC V5Z 4E6, Canada. ckollmannsberger@bccancer.bc.ca
authors: Christian
authors: C
authors: Kollmannsberger
authors: Teresa
authors: T
authors: Mitchell
mesh_terms: D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D003967:Diarrhea / Q000139:chemically induced; D005221:Fatigue / Q000139:chemically induced; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D011014:Pneumonia / Q000139:chemically induced; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects; D013280:Stomatitis / Q000139:chemically induced; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D058570:TOR Serine-Threonine Kinases